{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:34:28Z","timestamp":1790091268003,"version":"4.0.1"},"reference-count":13,"publisher":"Open Medical Publishing","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"\n Background<\/jats:title>\n Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive crises and chronic pain, often requiring multimodal analgesia that frequently includes opioids. Given the risks associated with long-term opioid therapy, there is a growing need for effective non-opioid alternatives. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, represents a novel analgesic approach targeting peripheral nociceptive signaling.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We present a case series of three patients with sickle cell-related pain treated with suzetrigine as part of a multimodal pain management strategy. The cohort included one patient with sickle cell trait (HbAS), one with hemoglobin SC disease, and one with hemoglobin SS disease. Clinical outcomes, including pain control, healthcare utilization, and medication use, were evaluated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Two of three patients reported subjective improvement in pain control with suzetrigine, including reduced reliance on opioid medications and no emergency department visits or hospitalizations during the observation period. Both patients were on minimal opioid therapy. In contrast, the third patient, who was maintained on chronic opioid therapy, did not experience improvement and required hospitalization for pain management. No adverse effects related to suzetrigine were observed in any patient.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Suzetrigine may be a non-opioid adjunct for managing sickle cell-related pain, particularly in opioid-na\u00efve or opioid-intolerant patients. However, its efficacy may be limited in opioid-tolerant individuals. Larger studies are needed to better define its role in the management of vaso-occlusive pain and chronic pain in SCD.<\/jats:p>\n <\/jats:sec>","DOI":"10.52965\/001c.162149","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:47:11Z","timestamp":1779468431000},"source":"Crossref","is-referenced-by-count":4,"title":["Suzetrigine for Vaso-Occlusive Pain in Sickle Cell Disease: A Three-Patient Case Series"],"prefix":"10.52965","volume":"18","author":[{"given":"Sami","family":"Joudeh","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darayon","family":"Moore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L","family":"Robinson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/037zgn354","id-type":"ROR","asserted-by":"publisher"}],"name":"Johns Hopkins Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupe","family":"Idowu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope","family":"Oso","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gds6c39","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas Health Science Center at Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"30777","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s40122-024-00697-0","article-title":"Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain","volume":"14","author":"J. D. Osteen","year":"2025","journal-title":"Pain Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.2147\/JPR.S527710","article-title":"Suzetrigine: Is This What We Have Been Waiting for or Just the Beginning?","volume":"18","author":"C. L. Robinson","year":"2025","journal-title":"J Pain Res"},{"issue":"2","key":"ref3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.64719\/pb.16578","article-title":"Suzetrigine for Pain Management: An Observational Study of Early Adoption Patterns","volume":"56","author":"J. Hasoon","year":"2026","journal-title":"Psychopharmacol Bull"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1097\/ALN.0000000000005460","article-title":"Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials","volume":"142","author":"T. Bertoch","year":"2025","journal-title":"Anesthesiology"},{"issue":"10533","key":"ref5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0140-6736(25)02278-0","article-title":"Sickle cell disease","volume":"407","author":"R. Colombatti","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle Cell Disease: A Review","volume":"328","author":"P. L. Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"16","key":"ref7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"F. B. Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ref8","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"A. M. Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management","volume":"105","author":"D. S. Darbari","year":"2020","journal-title":"Eur J Haematol"},{"issue":"38","key":"ref10","doi-asserted-by":"publisher","first-page":"e35237","DOI":"10.1097\/MD.0000000000035237","article-title":"Understanding Sickle cell disease: Causes, symptoms, and treatment options","volume":"102","author":"C. Elendu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"ref11","doi-asserted-by":"publisher","first-page":"e0216994","DOI":"10.1371\/journal.pone.0216994","article-title":"Chronic pain in adults with sickle cell disease is associated with alterations in functional connectivity of the brain","volume":"14","author":"M. S. Karafin","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"ref12","doi-asserted-by":"publisher","first-page":"CD012187","DOI":"10.1002\/14651858.CD012187.pub2","article-title":"Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults","volume":"2019","author":"T. E. Cooper","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"134534","DOI":"10.1016\/j.neulet.2019.134534","article-title":"Opioid treatment for acute and chronic pain in patients with sickle cell disease","volume":"714","author":"C. P. Carroll","year":"2020","journal-title":"Neurosci Lett"}],"container-title":["Orthopedic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/162149-suzetrigine-for-vaso-occlusive-pain-in-sickle-cell-disease-a-three-patient-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:47:11Z","timestamp":1779468431000},"score":1,"resource":{"primary":{"URL":"https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/162149-suzetrigine-for-vaso-occlusive-pain-in-sickle-cell-disease-a-three-patient-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":13,"URL":"https:\/\/doi.org\/10.52965\/001c.162149","relation":{},"ISSN":["2035-8164"],"issn-type":[{"value":"2035-8164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}